PROMOTER REGION rs1800629 TNFα POLYMORPHISM AND ITS INFLUENCE ON TUMOR NECROSIS FACTOR ALPHA CONCENTRATION IN BLOOD OF HEALTHY INDIVIDUALS AND PATIENTS WITH ERYSIPELAS

Erysipelas is an actual problem of health care. It is characterized by consistently high morbidity, excepted tendency to recur, reduced the life quality and took important place in the structure of temporary disability. The changes of immunological reactivity, depended on genetic characteristics of the individual were established to play important role in the pathogenesis of erysipelas. The prediction of the course of erysipelas is unresolved problem yet. The genetic features of the organism, such as the genetic polymorphisms of some cytokines, involved on the prediction of the course of erysipelas. Investigations of TNFα genes demonstrated that their transcriptions increased and productions enhanced. Aim was to study the influence of polymorphism of TNFα gene promoter rs1800629 on the concentration of TNFα in the blood of healthy individuals and patients with erysipelas in primary and recurrent course. The study was performed at 104 patients with erysipelas (54 patients with primary erysipelas and 50 patients with recurrent course) and 94 healthy residents. Gene polymorphism of TNFα rs1800629 was detected by PCR method. Measurement of the concentration of TNFα was performed by immunoassay analysis. Homo- and heterozygous SNP of the TNFα rs1800629 gene were conformed to Hardy–Weinberg equilibrium (p > 0.05). Minor allele A was found to be registered in erysipelas patient less frequently by 2.9 times than in healthy individuals. The patients who carried homozygous G/G were observed in 88.7% of cases. At that heterozygous G/A were registered in any case. In other case, among the patients, no cases of the carriage of the mutant genotypes A/A were detected. Thus, allele G and genotypes G/G of promoter gene of TNFα rs1800629 predisposed to erysipelas. Heterozygous G/A of promoter gene of TNFα rs1800629 increased the risk of erysipelas. G-allele carrier led to decrease of TNFα concentration homozygous G/G patients.

1. Bekenova N.B., Grzybowski, A.M., Mukovozova L.A., Smail E.M., Tokayeva A.Z. Rs8193036 polymorphism of IL-17A gene in a kazakh population and its association with plasma IL-17A among erysipelas patients. Ekologiya cheloveka = Human Ecology, 2016, no. 4, pp. 50-55. (In Russ.)

2. Gromova A.Yu., Simbirtsev A.S. Gene polymorphisms of interleukin 1 family cytokines. Tsitokiny i vospaleniye = Cytokines and Inflammation, 2005, Vol. 4, no. 2, pp. 5-7. (In Russ.)

3. Emelyanov A.S., Emelyanova A.N., Pushkarev, B.S., Vitkovsky Yu.A. Promoter gene IL1B (G1473С) polymorphism and its influence on interleukin 1B concentration in blood of patients with erysipelas. Meditsinskaya genetika = Medical Genetics, 2017, Vol. 16, no. 8, pp. 32-35. (In Russ.)

4. Emelyanova A.N., Vitkovsky Yu.A. Erysipelas (pathogenesis, features of course). Tomsk: Ivan Fedorov, 2014. 132 p.

5. Emelyanova A.N., Emelyanov A.S., Vitkovsky Yu.A. The genetic polymorphism of promoter gene IL-2 (T330G) and its influence on the maintenance of interleukin 2 in blood of patients with the erysipelas. Zabaykal`skiy meditsinskiy vestnik = Transbaikalian Medical Bulletin, 2014, no. 2, pp. 98-103. (In Russ.)

6. Naslednikova I.O., Urazova O.I., Voronkova O.V. Immunopathogenesis of bacterial and viral infections: role of cytokine gene polymorphism. Allergologiya i immunologiya = Allergology and Immunology, 2008, Vol. 9, no. 3, p. 294. (In Russ.)

7. Petrov A.A., Strambovskaya N.N., Govorin A.V., Vitkovsky Yu.A. Genetic polymorphisms of CD14, TNFα and FCGR2A in the patients with influenza A H1N1 in Transbaikalian region. Meditsinskaya immunologiya = Medical Immunology (Russia), 2011, Vol. 13, no. 1, pp. 83-86. (In Russ.) doi:10.15789/1563-06252011-1-83-86.

8. Pshenichnaya N.Yu., Moskovaya T.V., Shishkanova L.V., Pasechnik D.G. Diagnostic and prognostic value of proinflammatory adipokines in patients with erysipelas of the lower extremities. Sovremennye problemy nauki i obrazovaniya = Modern Problems of Science and Education, 2015, no. 3, p. 31. (In Russ.)

9. Simbirtsev A.S. Cytokines as a new system, regulating body defense reactions. Tsitokiny i vospalenie = Cytokines and Inflammation, 2002, no. 1, pp. 9-16. (In Russ.)

10. Cherkasov V.L. Erysipelas]. Leningrad: Medicine, 1986. 200 p.

11. Ashkenazi A., Marsters S.A., Capon D.J., Chamow S.M., Figari I.S., Pennica D., Goeddel D.V., Palladino M.A., Smith D.H. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Procl. Natl. Acad. Sci., 1991, no. 88, pp. 10535-10539.

12. Vitkovsky Yu. Interleukins modulate fibrinolytic properties of lymphocytes. Fibrinolysis and Proteolysis, 2000, Vol. 14, Suppl. 1, p. 68.

13. Beutler В., Grau G. Tumor necrosis factor in the pathogenesis of infectious diseases. Crit. Care Med.,1993, Vol. 21, pp. 423-435.

14. Stuber F., Petersen M., Bokelmann F., Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit. Care Med., 1996, Vol. 24. pp. 381-384.